

WHITE PAPER

ACCESS (CMS), TEMPO (FDA) AND CIRCLE DATASETS

February 2026

TABLE OF CONTENTS

EXECUTIVE SUMMARY	2
CHALLENGES ADDRESSED BY ACCESS AND TEMPO	2
OPERATIONAL MECHANICS OF THE ACCESS AND TEMPO MODELS	3
CMS ACCESS: THE SHIFT TO OUTCOME-ALIGNED PAYMENTS.....	3
FDA TEMPO: ENABLING EVIDENCE GENERATION IN REAL-LIFE SETTINGS.....	4
THE SYNERGISTIC LOOP: HOW ACCESS AND TEMPO WORK TOGETHER	5
MEDICAL AREAS OF IMPACT. THE VALUE OF OUTCOME ENGINEERING	5
CARDIO-KIDNEY-METABOLIC (CKM) INTEGRATION	5
MUSCULOSKELETAL (MSK) HEALTH AND FUNCTIONAL RECOVERY.....	6
BEHAVIORAL HEALTH AND CHRONIC DISEASE MANAGEMENT	6
CIRCLES DATASETS: EXPLOITING THE VERACITY MANDATE	7
GENERAL STRATEGIC USE.....	7
<i>For Providers</i>	7
<i>For Payers</i>	7
<i>For Industry</i>	7
ORTHOPEDICS: VALIDATING HYPOTHESES IN MUSCULOSKELETAL INNOVATION	7
ONCOLOGY: MANAGING SIDE EFFECTS AND JUSTIFYING PREMIUM PRICING	8
SMOKING CESSATION: LEVERAGING "TEACHABLE MOMENTS" FOR MORTALITY REDUCTION.....	8
CONCLUSION: THE STRATEGIC PATH TO HIGHER BUSINESS VALUATION.....	9
REFERENCES.....	10